Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FABP3 | P05413 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841030 | 0.95 | MAPK14 (0.41) | MAPK14PDE10ALPAR2CTSAFFAR1 | |
| SCHEMBL4833047 | 0.93 | MAPK14 (0.41) | MAPK14LPAR2CTSAFFAR1MAPK11 | |
| SCHEMBL4844592 | 0.92 | MAPK14 (0.43) | MAPK14PDE10ALPAR2CTSAFFAR1 | |
| SCHEMBL4837199 | 0.89 | DGAT2 (0.42) | MAPK14LPAR2CTSAMAPK11 | |
| SCHEMBL4841418 | 0.89 | MAPK14 (0.41) | MAPK14LPAR2MAPK11 | |
| SCHEMBL4845132 | 0.87 | MAPK14 (0.41) | MAPK14LPAR2CTSAFFAR1MAPK11 | |
| SCHEMBL4833067 | 0.87 | MAPK14 (0.42) | MAPK14MAPK11 | |
| SCHEMBL4017385 | 0.87 | MAPK14 (0.41) | MAPK14LPAR2CTSAMAPK11 | |
| SCHEMBL4840538 | 0.87 | KMT2A (0.38) | MAPK14 | |
| SCHEMBL4013138 | 0.86 | MAPK14 (0.43) | MAPK14CTSAMAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | claimed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435731-B2 | Substituted pyrazolo[3,4-d]pyrimadines and methods of using the same | ROCHE PALO ALTO LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | ROCHE PALO ALTO LLC | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197340-A1 | Fused-pyrazolo pyrimidine and pyrazolo pyrimidinone derivatives and methods for using the same | MAP3K1, MAPK1, MAP3K8 | MAPK14 70/4885PDE10A 1562/4885LPAR2 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.